Alzheimer's Disease: Aging, Insomnia and Epigenetics

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://140.112.115.32:8080/ir/handle/987654321/1198

题名:	Alzheimer's Disease: Aging, Insomnia and Epigenetics
作者:	Tzong-Yuan Wu;Chih-Ping Chen;Tzyy-Rong Jinn
贡献者:	生醫所
日期:	2010-12-01
上传时间:	2015-03-16 15:40:39 (UTC+8)
摘要:	Alzheimer's disease (AD) is the most common form of dementia. Severe memory loss, confusion, and impaired cognitive abilities characterize AD. It was only a century after Alzheimer's discovery that scientists were able to shed light on the mystery of its cause, but AD has also become a globally important health issue and the treatment of AD is a challenge for modern medicine. At present, there are five drugs approved in the United States for the treatment of AD, namely, donepezil, galantamine, rivastigmine, and tacrine (which are all cholinesterase inhibitors); and memantine (which is a glutamate receptor antagonist). However, these drugs show only modest effects on AD patients. Thus, new investigations are necessary for pharmacological development in AD. This brief review focuses on new studies that demonstrate the link between epigenetics and AD, and explores the possibility that insomnia may be one factor that effects AD.
關聯:	Taiwanese Journal of Obstetrics and Gynecology, 49(4), 468-472. doi:10.1016/S1028-4559(10)60099-X https://doi.org/10.1016/S1028-4559(10)60099-X
显示于类别:	[生物醫學研究所] 期刊論文

文件中的档案:

档案	大小	格式	浏览次数
index.html	0Kb	HTML	158	检视/开启

在MMCIR中所有的数据项都受到原著作权保护.